Vaxart, Inc. operates as a clinical-stage biotechnology company, which engages in the development of oral recombinant vaccines based on its Vector-Adjuvant-Antigen Standardized Technology oral vaccine platform. The company is headquartered in South San Francisco, California and currently employs 105 full-time employees. Its vaccines are designed to be administered using pills that can be stored and shipped without refrigeration and eliminate the risk of needle-stick injury. The Company’s development programs include pill vaccines designed to protect against coronavirus, norovirus and influenza, as well as a therapeutic vaccine for human papillomavirus (HPV), its first immune-oncology indication. The firm's platform technology employs a vector-based approach and consists of various components, such as vector, antigen, and adjuvant. A vector is a virus used as a carrier to deliver DNA coding for vaccine antigens and an adjuvant selected to activate the immune system. An antigen is a viral or bacterial protein that stimulates an immune response to the targeted pathogen.
Follow-Up Questions
Who is the CEO of Vaxart Inc?
Mr. Steven Lo is the President of Vaxart Inc, joining the firm since 2024.
What is the price performance of VXRT stock?
The current price of VXRT is $0.36, it has decreased 0% in the last trading day.
What are the primary business themes or industries for Vaxart Inc?
Vaxart Inc belongs to Biotechnology industry and the sector is Health Care
What is Vaxart Inc market cap?
Vaxart Inc's current market cap is $82.4M
Is Vaxart Inc a buy, sell, or hold?
According to wall street analysts, 4 analysts have made analyst ratings for Vaxart Inc, including 4 strong buy, 4 buy, 1 hold, 0 sell, and 4 strong sell
